Sanofi reported third-quarter net sales growth of 14% and business EPS growth of 20% at constant currencies. Management upgraded full-year guidance to low-teens sales growth, up from around 10%, and mid-teens business EPS growth. Ordinary shares closed up 5% from the previous day's close.
Immunology drug Dupixent holds strong pricing power and market share across several indications.
Sanofi suffered several disappointing readouts starting in 2025, adding pressure to develop or acquire assets that could replace Dupixent before its loss of exclusivity.
|
Metric
|
SAN
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 13.21 | 16.40 | 165.74 |
Price/Book Value | 1.31 | 8.16 | 8.80 |
Price/Sales | 1.89 | 5.38 | 5.49 |
Price/Cash Flow | 8.05 | 15.80 | 16.74 |
|
Metric
|
SAN
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.21 | 0.58 | 0.71 |
Current Ratio | 1.12 | 0.88 | 1.32 |
Interest Coverage | 9.10 | 8.78 | 4.28 |
|
Metric
|
SAN
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 8.44% | 14.70% | 6.27% |
Return on Equity (Normalized) | 15.62% | 40.76% | 16.68% |
Return on Invested Capital (Normalized) | 12.02% | 21.22% | 9.74% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|l&^Bn%! | LOCK|byh | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|pQX?#m% | LOCK|S% | $658B | |||
| AbbVie Inc
ABBV
| LOCK|$>>hjRV | LOCK|WJ$ | $521B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|K>%p^L^ | LOCK|rH | $391B | |||
| Merck & Co Inc
MRK
| LOCK|W%?h>> | LOCK|!P | $369B | |||
| Novartis AG ADR
NVS
| LOCK|l%%<!W!g | LOCK|Hm> | $307B | |||
| AstraZeneca PLC
AZN
| LOCK|>Pq!<&# | LOCK|P&V | $290B | |||
| Amgen Inc
AMGN
| LOCK|W&F>#KyD | LOCK|SW | $252B | |||
| Gilead Sciences Inc
GILD
| LOCK|rNx!%B& | LOCK|W%c | $212B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|k@M!M>P | LOCK|V? | $176B |
United States